- Home
- SKWD vs OCS Comparison
SKWD vs OCS Comparison
Compare SKWD & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | OCS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKWD | OCS |
|---|---|---|
| Price | $50.56 | $11.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $64.63 | $42.00 |
| AVG Volume (30 Days) | 327.3K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,416,541,000.00 | N/A |
| Revenue This Year | $29.54 | $466.06 |
| Revenue Next Year | $12.64 | $479.73 |
| P/E Ratio | $46.00 | ★ N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $40.60 | $10.52 |
| 52 Week High | $58.18 | $34.48 |
Technical Indicators
Market Signals| Indicator | SKWD | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 24.07 |
| Support Level | $43.39 | $10.52 |
| Resistance Level | $53.54 | $21.50 |
| Average True Range (ATR) | 1.57 | 1.05 |
| MACD | 0.49 | -0.07 |
| Stochastic Oscillator | 87.99 | 12.77 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.